Small study tackles nasty side effect of lung drug
NCT ID NCT06200714
First seen May 20, 2026
Summary
This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. Researchers tracked how many patients had fewer than 3 loose stools per day. It is an observational study, meaning no new treatment was tested—just real-world data collection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Germans Trias i Pujol
Barcelona, 08916, Spain
-
Hospital Universitario Virgen de las Nieves
Granada, 18014, Spain
-
Hospital Universitario de Cruces
Bizkaia, 48903, Spain
-
Hospital de La Princesa
Madrid, 28006, Spain
-
Hospital Álvaro Cunqueiro
Pontevedra, 36312, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib (OFEV)
What this could lead to
If successful, this could help doctors manage a common side effect of nintedanib, allowing patients to stay on their lung fibrosis treatment with less discomfort.
What could go wrong
This is a very small observational study (18 people) with no control group, so results may not apply to everyone. It only looks at diarrhea control, not whether the drug works for the lung disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.